TITLE:
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

CONDITION:
Macular Degeneration

INTERVENTION:
Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL

SUMMARY:

      The purpose of this study is to investigate the long-term efficacy and safety of posterior
      juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 50 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patients with subfoveal exudative age-related macular degeneration (AMD) who were
             previously enrolled in long-term studies with anecortave acetate.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Other protocol-defined exclusion criteria may apply.
      
